Skip to main content
Log in

Concurrent BRAF V600E mutated papillary thyroid carcinoma and Erdheim–Chester disease

  • Endocrine Imaging
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. E.L. Diamond, L. Dagna, D.M. Hyman, G. Cavalli, F. Janku, J. Estrada-Veras, M. Ferrarini, O. Abdel-Wahab, M.L. Heaney, P.J. Scheel, N.K. Feeley, E. Ferrero, K.L. McClain, A. Vaglio, T. Colby, L. Arnaud, J. Haroche, Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124, 483–492 (2014)

    Article  CAS  Google Scholar 

  2. F. Cohen Aubart, J.F. Emile, F. Carrat, F. Charlotte, N. Benameur, J. Donadieu, P. Maksud, A. Idbaih, S. Barete, K. Hoang-Xuan, Z. Amoura, J. Haroche, Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 130, 1377–1380 (2017)

    Article  Google Scholar 

  3. A. Zaidi, U. Gautam, R. Srinivasan, A. Bal, G. Prakash, A. Sood, Challenging diagnosis of two neoplasms, Langerhans cell histiocytosis and papillary thyroid carcinoma from fine needle aspiration of the thyroid by cell block immunocytochemistry and molecular testing for BRAFV600E mutation. Cytopathology. (2020). https://doi.org/10.1111/cyt.12816

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alberto Cuocolo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klain, M., Schlumberger, M. & Cuocolo, A. Concurrent BRAF V600E mutated papillary thyroid carcinoma and Erdheim–Chester disease. Endocrine 70, 655–656 (2020). https://doi.org/10.1007/s12020-020-02317-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-020-02317-1

Navigation